The National Center for Tumor Diseases (NCT) Heidelberg is holding its 19th Cancer Patient Day on 27 April 2024. The online event will feature specialist lectures and expert forums on various cancers, with self-help groups also participating. At the Cancer Patients' Day, patients, relatives and all interested parties can learn about oncological research and treatment first-hand. Registration is possible until 24 April via this link: https://indico.dkfz.de/e/Krebspatiententag2024
The NCT Heidelberg is a joint institution of the German Cancer Research Center (DKFZ) and Heidelberg University Hospital (UKHD).
The 19th Cancer Patient Day at the NCT Heidelberg will take place as a video conference on 27 April from 9.30 am to 1 pm. In six specialist presentations, news from oncological research and treatment as well as support services will be presented in an understandable way. In addition, self-help and patient representatives from the NCT Heidelberg will introduce themselves. Afterwards, participants will be able to discuss various forms of the disease with experts from the clinic, research and self-help groups in interactive expert forums and ask them questions.
Dirk Jäger, Managing Director at the NCT Heidelberg and Head of Medical Oncology at Heidelberg University Hospital (UKHD), states: "The Cancer Patient Day provides all interested parties with information on oncological therapies and from the active self-help network in a direct way." Previous years have seen over 300 guests attend each Cancer Patient Day. The Cancer Patient Day 2024 will once again take place online via Zoom and will be automatically subtitled live. Stefan Fröhling, Managing Director at the NCT Heidelberg and Head of the Department of Translational Medical Oncology at the German Cancer Research Center (DKFZ), says: "We know that participants appreciate the ease of access to the Cancer Patient Day and hope that there will once again be great interest."
The Cancer Patients' Day of the NCT Heidelberg is under the patronage of the Lord Mayor of the City of Heidelberg, Eckart Würzner, and the Baden-Württemberg Cancer Association. The Heidelberg self-help office also supports the event.
The sponsors are AstraZeneca, MSD Sharp & Dohme, Merck Healthcare Germany, Roche Pharma and Abnoba.
Topics of the specialist presentations
- Modern therapy concepts in radiotherapy
- Molecular oncology
- Innovative surgery of malignant tumors in the abdomen
- Immunotherapy
- Exercise - an important "drug" in modern cancer therapy
- Patients as research partners
Topics of the expert forums
- Breast cancer
- Gynecological tumors
- Kidney, bladder and prostate cancer
- Gastrointestinal and neuroendocrine tumors
- Head and neck tumors
- Brain tumors and metastases
- Thoracic tumors
- Leukemias, lymphomas and multiple myeloma
- Sarcomas, CUP, bone and soft tissue tumors
- Skin cancer
Registration information and contact
19th Cancer Patient Day of the NCT Heidelberg
April 27, 2023
9.30 a.m. to 1 p.m.
Online event via Zoom
Register online by April 24 at https://indico.dkfz.de/e/Krebspatiententag2024
Participation is free of charge. Please note that the event will be held in German.
Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg
Fortbildungen und Veranstaltungen
Im Neuenheimer Feld 460
69120 Heidelberg
Telefon: (06221) 56-36091
E-Mail: nct.events@nct-heidelberg.de
Organiser: Heidelberg University Hospital
Media representatives are invited to attend the Cancer Patient Day. Please contact Martin Staiger; see below for contact details.
Images for the press release are available free of charge at:
https://www.nct-heidelberg.de/fileadmin/media/nct-heidelberg/news/Meldungen/Bilder/NCT_Patiententag2024.jpg
Note on the use of images for press releases
Use is free of charge. The NCT Heidelberg permits one-time use in connection with reporting on the subject of the press release. Please indicate the copyright "Beweg Dich gegen Krebs" as picture credits. The image material may only be passed on to third parties after prior consultation with NCT Communications (Phone: +49 6221 42-1755, e-mail: martin.staiger@nct-heidelberg.de). Use for commercial purposes is prohibited.
Press contact:
Dr. Martin Staiger
Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg
Kommunikation und Veranstaltungen
Im Neuenheimer Feld 460
69120 Heidelberg
Tel.: +49 6221 42-1755
E-Mail: martin.staiger@nct-heidelberg.de
www.nct-heidelberg.de
Dr. Sibylle Kohlstädt
Deutsches Krebsforschungszentrum (DKFZ)
Strategische Kommunikation und Öffentlichkeitsarbeit
Im Neuenheimer Feld 280
69120 Heidelberg
Tel.: +49 6221 42-2843
Fax: +49 6221 42-2968
E-Mail: s.kohlstaedt@dkfz.de
www.dkfz.de
Dr. Stefanie Seltmann
Universitätsklinikum Heidelberg und Medizinische Fakultät der Universität Heidelberg
Presse- und Öffentlichkeitsarbeit
Im Neuenheimer Feld 672
69120 Heidelberg
Tel.: +49 6221 56-5052
Fax: +49 6221 56-4544
E-Mail: stefanie.seltmann@med.uni-heidelberg.de
www.klinikum.uni-heidelberg.de
The National Center for Tumor Diseases (NCT) Heidelberg
The National Center for Tumor Diseases (NCT) Heidelberg is a joint institution of the German Cancer Research Center, Heidelberg University Hospital and German Cancer Aid. The NCT's goal is to link promising approaches from cancer research with patient care from diagnosis to treatment, aftercare and prevention. The interdisciplinary tumor outpatient clinic is the central element of the NCT. Here the patients benefit from an individual treatment plan prepared in a timely manner in interdisciplinary expert rounds, the so-called tumor boards. Participation in clinical studies provides access to innovative therapies. The NCT thereby acts as a pioneering platform that translates novel research results from the laboratory into clinical practice. The NCT cooperates with self-help groups and supports them in their work. The pediatric oncologists at the KiTZ work together in joint structures with the NCT Heidelberg.
German Cancer Research Center (DKFZ)
With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.
To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:
- National Center for Tumor Diseases (NCT, 6 sites)
- German Cancer Consortium (DKTK, 8 sites)
- Hopp Children's Cancer Center (KiTZ) Heidelberg
- Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
- DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
- National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.
Heidelberg University Hospital and Faculty of Medicine: Internationally Renowned Patient Care, Research and Teaching
Heidelberg University Hospital (Universitätsklinikum Heidelberg, UKHD) is one of the largest and most prestigious medical centers in Germany. The Medical Faculty of Heidelberg University (Medizinische Fakultät Heidelberg, MFHD) belongs to the internationally renowned biomedical research institutions in Europe. Both institutions have the common goal of developing new therapies and implementing them rapidly for patients. Heidelberg University Hospital and the Medical Faculty of Heidelberg University employs around 14.500 employees and is committed to providing trainings and qualifications. Every year, around 86,000 patients and more than 1.100.000 outpatient cases are treated in more than 50 clinical departments with almost 2.500 beds. Together with the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the German Cancer Aid, the UKHD established the first National Center for Tumor Diseases (NCT) in Heidelberg. The goal is to provide care at the highest level as an oncology center of excellence and to rapidly transfer promising approaches from cancer research to the hospital. In addition, the UKHD operates in partnership with the DKFZ and the University of Heidelberg the Hopp Children’s Cancer center Heidelberg (KiTZ), a unique and nationally known therapy and research center for oncological and hematological diseases in children and adolescents. The Heidelberg Curriculum Medicinale (HeiCuMed) is one of the top medical training programs in Germany. Currently, there are about 4.000 future physicians studying in Heidelberg.